
    
      This is a Phase 1 multicenter, open-label study to evaluate the safety, pharmacokinetics,
      pharmacodynamics, immunogenicity, and antitumor activity of MEDI0562 in combination with
      immune therapeutic agents in adult subjects with select advanced solid tumors.
    
  